Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1320159
European Journal of Endocrinology, Vol 132, Issue 2, 159-162
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, K.-O.
Right arrow Articles by Ratnam, S. S
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lee, K.-O.
Right arrow Articles by Ratnam, S. S

Effect of growth hormone therapy in men with severe idiopathic oligozoospermia

Kok-Onn Lee, Soon-Chye Ng, Pheng-Soon Lee, Ariff T Bongso, Elizabeth A Taylor, Ting-Kwong Lin and Shan S Ratnam

Lee K-O, Ng S-C, Lee P-S, Bongso AT, Taylor EA, Lin T-K, Ratnam SS. Effect of growth hormone therapy in men with severe idiopathic oligozoospermia. Eur J Endocrinol 1995;132:159–62. ISSN 0804–4643

Some studies have suggested that growth hormone (GH) may enhance folliculogenesis in women, and similarly may enhance spermatogenesis in men with hypogonadotrophic hypogonadism. In this prospective open-controlled pilot study, we investigated the effect of daily subcutaneous GH for 5 months in 12 endocrinologically normal men with severe idiopathic oligozoospermia (< 10 million/ ml). All the men had normal karyotype and endocrine tests, including a GH response of > 20 000 mU/l to insulin hypoglycaemia. Nine men with similar sperm counts acted as controls. During treatment, each patient was examined monthly, asked for side effects and had glycosylated haemoglobin, glucose and blood counts monitored. Five semen samples were obtained in the 4 months before treatment, two samples per month during treatment and three samples after stopping treatment. The mean insulinlike growth factor I (IGF-I) was normal before treatment and 1 month after ending treatment, at 206 and 182 µg/l, respectively, but increased significantly during treatment to 444 µg/l (p < 0.0001, ANOVA). The mean (sd) sperm counts were 2.6 (2.5), 2.5 (3.7) and 2.3 (2.1) million/ml before, during and after GH treatment, respectively, and did not show any statistically significant differences (ANOVA). We conclude that GH does not increase or decrease sperm counts in men with severe idiopathic oligozoospermia.

K-O Lee, Division of Endocrinology, Department of Medicine, National University of Singapore, Kent Ridge, Singapore 0511







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.